Tag Archives: Alan Carr

Lexicon Pharmaceuticals (LXRX) Receives a Hold from Needham

In a report released today, Alan Carr from Needham assigned a Hold rating to Lexicon Pharmaceuticals (LXRX – Research Report). The company’s shares closed last Thursday at $1.95. According to TipRanks.com, Carr is a 2-star analyst with an average return

Needham Reiterates a Buy Rating on Albireo Pharma (ALBO)

In a report released today, Alan Carr from Needham reiterated a Buy rating on Albireo Pharma (ALBO – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $25.39. According to TipRanks.com, Carr is a

ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from Needham

In a report released today, Alan Carr from Needham assigned a Buy rating to ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $60.00. The company’s shares closed last Tuesday at $44.84. According to TipRanks.com, Carr is a

Needham Releases a Buy Rating on Tricida (TCDA)

Needham analyst Alan Carr assigned a Buy rating to Tricida (TCDA – Research Report) today and set a price target of $50.00. The company’s shares closed last Thursday at $15.37. According to TipRanks.com, Carr is a 4-star analyst with an

Needham Believes Moderna (NASDAQ: MRNA) Still Has Room to Grow

In a report released today, Alan Carr from Needham assigned a Buy rating to Moderna (MRNA – Research Report), with a price target of $94.00. The company’s shares closed last Wednesday at $84.19, close to its 52-week high of $87.00.

Needham Releases a Hold Rating on Gilead Sciences (GILD)

In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed last Monday at $74.56. According to TipRanks.com, Carr is a 2-star analyst with an average return